MSK Head and Neck Cancer: Thyroid Cancer Research Update Clinicians and scientists at MSK continue to investigate new ways to improve outcomes for patients with thyroid cancer. Recent research insights from MSK thyroid cancer experts include, the safety and...

MSK researchers are advancing the standard of care for treating head and neck cancers, including #thyroidcancer. Recent work highlights progress in areas such as active surveillance, identification of mutation profiles, #redifferentiation therapy, and more.

Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement In patients with follicular cell-derived thyroid cancer that have distant metastases and no iodine uptake, redifferentiation—ie, the restoration of tumoural 131I uptake with systemic therapy—is now po...

Redifferentiation treatment has become a more accepted treatment strategy in patients with [radioiodine refractory] RAIR #thyroid #cancer with targetable mutations suitable for a #redifferentiation approach www.thelancet.com/journals/lan...
#thyroidcancer
#OpenAccess

#MedSky #EndoSky #OncSky